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Summary
The landscape of medical sequencing has rapidly changed
with the evolution of next generation sequencing (NGS).
These technologies have contributed to the molecular charac-
terization of the myelodysplastic syndromes (MDS) and
chronic myelomonocytic leukaemia (CMML), through the
identification of recurrent gene mutations, which are present
in >80% of patients. These mutations contribute to a better
classification and risk stratification of the patients. Currently,
clinical laboratories include NGS genomic analyses in their
routine clinical practice, in an effort to personalize the diag-
nosis, prognosis and treatment of MDS and CMML. NGS
technologies have reduced the cost of large-scale sequencing,
but there are additional challenges involving the clinical vali-
dation of these technologies, as continuous advances are con-
stantly being made. In this context, it is of major importance
to standardize the generation, analysis, clinical interpretation
and reporting of NGS data. To that end, the Spanish MDS
Group (GESMD) has expanded the present set of guidelines,
aiming to establish common quality standards for the ade-
quate implementation of NGS and clinical interpretation of
the results, hoping that this effort will ultimately contribute
to the benefit of patients with myeloid malignancies.
Keywords: myelodysplastic syndromes, chronic myelomono-
cytic leukaemia, next generation sequencing, guidelines,
molecular genetics.
The development of next generation sequencing (NGS) tech-
niques during the last decade has contributed to the molecu-
lar characterization of haematological malignancies, including
myeloid neoplasms, such as the myelodysplastic syndromes
(MDS) and chronic myelomonocytic leukaemia (CMML)
(Arber et al, 2016). According to the World Health Organi-
zation (WHO) classification (Arber et al, 2016), MDS
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comprise a group of clonal haematopoietic stem cell disor-
ders characterized by ineffective haematopoiesis in one or
more myeloid cell lines, abnormal dysplastic cell morphology
and potential for clonal evolution. On the other hand,
CMML is included in the WHO group of myelodysplastic/
myeloproliferative neoplasms (MDS/MPN) and is character-
ized by absolute peripheral monocytosis in conjunction with
both effective (myeloproliferative variant, MP-
CMML ≥ 13 9 109/l leucocytes) and ineffective (myelodys-
plastic variant, MD-CMML < 13 9 109/l leucocytes) haema-
topoiesis. MDS and CMML are very heterogeneous at the
clinical, morphological and genetic level and both and have
the risk of progressing to acute myeloid leukaemia (AML).
The natural history of these diseases is highly variable and a
risk-adapted treatment strategy is mandatory.
Myeloid neoplasms arise through the serial acquisition of
chromosomal alterations and somatic mutations that affect
genes involved in several mechanisms. These mutations drive
disease evolution from asymptomatic clonal haematopoiesis
to overt disease and, eventually, progression to AML (Ken-
nedy & Ebert, 2017). Recurrent mutations in more than 40
different genes have been identified in MDS and CMML and
at least one mutation is detected at diagnosis in >80% of
patients (Papaemmanuil et al, 2013; Haferlach et al, 2014;
Elena et al, 2016). These mutations are related to the patho-
physiological features of these diseases and play a role in
their clinical heterogeneity. These molecular markers can
complement current diagnostic criteria in MDS and CMML,
as well as contribute to the risk assessment of these patients
(Bejar et al, 2011; Haferlach et al, 2014; Elena et al, 2016).
Therefore, diagnostic laboratories are including NGS geno-
mic analyses in their routine clinical practice, in an effort to
personalize the diagnosis, prognosis and treatment of MDS
and CMML. Thorough evaluation of technical aspects, data
analysis and variant interpretation is required for the correct
implementation of NGS in routine diagnosis. Thus, the aim
of this collaborative project within the Spanish MDS Group
(GESMD) was to develop a set of guidelines, agreed by
expert consensus panels, to standardize the use of targeted
deep sequencing in the routine genetic testing of MDS and
CMML patients, for the detection of single nucleotide vari-
ants (SNVs) and small insertions/deletions (indels). Our
main objective is to harmonize analyses and variant interpre-
tation, ensuring high standards in clinical reporting of
genetic data. These consensually proposed NGS guidelines
involve the following major sections, which will be further
discussed in detail: (i) mutational landscape in MDS and
CMML, (ii) sequencing workflow and quality control, (iii)
data analysis and variant filtering, (iv) variant categorization/
interpretation and (v) clinical reports.
Mutational landscape of MDS and CMML
Over 40 different genes are found recurrently mutated in
MDS and CMML (Papaemmanuil et al, 2013; Haferlach
et al, 2014; Elena et al, 2016). However, in contrast to other
diseases, such as myeloproliferative neoplasms (MPN), none
of them are specific to these disorders. Still, a few of these
genes have been proved to be useful for diagnosis or to pre-
dict response to specific treatments (Papaemmanuil et al,
2011; Itzykson et al, 2011; Bejar et al, 2014; Traina et al,
2014). Moreover, some mutations are also associated with
shorter survival and a higher risk of progression to AML and
therefore can be used for prognostic stratification (Table I)
(Bejar et al, 2011, 2012; Papaemmanuil et al, 2013; Haferlach
et al, 2014; Elena et al, 2016; Makishima et al, 2017). Thus,
an MDS/CMML targeted sequencing panel should at least
include all those genes that have been proven relevant for the
disease (Malcovati et al, 2013; Arber et al, 2016; Greenberg
et al, 2017) (Table II). As NGS is a high throughput tech-
nique, it can be complemented with genes that are altered in
other myeloid neoplasms to generate a pan-myeloid sequenc-
ing panel, in view of a wider utility of the tool (e.g. for
MDS, MPN and AML) (Table III). In this regard, the Associ-
ation for Molecular Pathology recently reviewed the clinical
relevance of small DNA variants in chronic myeloid neo-
plasms, summarizing key findings that support clinical util-
ity, and defining the need for gene inclusion in high-
throughput sequencing testing panels (McClure et al, 2018).
Driver genes in MDS and CMML, which are common
among the spectrum of myeloid malignancies, affect specific
cellular processes and can be categorized according to their
function (Greenberg et al, 2017; Kennedy & Ebert, 2017;
McClure et al, 2018) (Fig 1).
Mutations in RNA-splicing machinery are the most fre-
quent type of somatic mutations detected in MDS. Recurrent
mutations have been reported in the spliceosome compo-
nents of the SF3B1, SRSF2, U2AF1 and ZRSR2 genes, while
mutations in PRPF40B, SF3A1, SF1 and U2AF2 (U2AF65)
genes have been described in only 1–2% of MDS patients
(Yoshida et al, 2011; Makishima et al, 2012; Papaemmanuil
et al, 2013). SF3B1 mutations are associated with a higher
overall survival rate and an inferior risk of AML progression,
as they are the only ones that are clearly associated with a
better prognosis, especially as a single mutation (Papaem-
manuil et al, 2011; Malcovati et al, 2014). SRSF2 mutations
are associated with monocytosis and marked thrombo-
cythaemia and are especially frequent in CMML (Yoshida
et al, 2011; Meggendorfer et al, 2012). Mutations in SRSF2
and U2AF1 have been associated with less favorable out-
comes in some studies (Graubert et al, 2011; Thol et al,
2012; Meggendorfer et al, 2012; Haferlach et al, 2014; Mak-
ishima et al, 2017).
Epigenetic regulators are the second most common class
of mutation in MDS, and can be divided into DNA
methylation enzymes (TET2, DNMT3A and IDH1/2 genes)
and chromatin modifiers (ASXL1 and EZH2 genes) (Del-
hommeau et al, 2009; Walter et al, 2011; Gelsi-Boyer et al,
2012; Shih et al, 2012; Ganguly & Kadam, 2016). TET2
mutations are very common in CMML and the
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combination of TET2 and SRSF2 is highly associated with
this disorder (Malcovati et al, 2014). TET2 mutations do
not have a prognostic impact but they are associated with
an increased response rate to hypomethylating agents
(Itzykson et al, 2011; Bejar et al, 2014) (Table III).
DNMT3A mutations are associated with a more aggressive
clinical course and rapid progression to AML in both
MDS and CMML patients (Walter et al, 2011; Bejar et al,
2014; Patnaik et al, 2017). ASXL1 mutations are indepen-
dently associated with a poor outcome in the spectrum of
myeloid diseases, including a shorter overall survival and a
higher risk of progression to AML (Boultwood et al, 2010;
Gelsi-Boyer et al, 2012; Itzykson et al, 2013a). EZH2 muta-
tions are associated with worsened overall survival in both
low and high risk MDS and CMML (Bejar et al, 2011;
Grossmann et al, 2011; Bejar et al, 2012).
The multiprotein cohesin complex is involved in the cohe-
sion of sister chromatids and the post-replicative DNA repair
system, and it is encoded by the genes STAG1/2, SMC1A,
SMC3 and RAD21, which are mutated in up to 11% of low
risk and 17% of high risk MDS patients (Kon et al, 2013;
Thota et al, 2014). Mutations in STAG2 are more frequent in
patients with multilineage dysplasia and excess of blasts and
seem to be associated with shorter overall survival (Thota
et al, 2014).
Loss-of-function mutations in a transcription factor gene,
such as RUNX1, GATA2 or ETV6, are detected in approxi-
mately 20% of MDS (Chen et al, 2007; Bejar et al, 2011;
Wall et al, 2012). RUNX1 mutations are associated with a
high risk phenotype, thus being more frequent in high risk
MDS and CMML and in secondary AML (Bejar et al, 2011;
Cazzola et al, 2013; Elena et al, 2016).
MDS and CMML patients frequently harbour mutations
in signal transduction genes, which constitutionally activate
a signalling pathway involved in cell proliferation, apoptosis
and cell differentiation (CBL, CSNK1A1, JAK2, N/KRAS,
MPL, NF1, PTPN11, KIT, and FLT3 genes). These muta-
tions are more frequent in myeloproliferative CMML cases
and usually correspond to secondary events that may lead
to AML progression (Pich et al, 2009; Kohlmann et al,
2010; Ricci et al, 2010; Schwaab et al, 2012; Itzykson et al,
2013b; Smith et al, 2015; Elena et al, 2016).
Table I. Clinical relevance of mutated genes in MDS and CMML (Malcovati et al, 2013; Arber et al, 2016; Greenberg et al, 2017).
Gene
MDS CMML
Incidence Clinical impact Incidence Clinical impact
ASXL1 5–25% Unfavourable 40–50% Unfavourable
CSNK1A1 <1%
5–15% MDS with del(5q)
Uncertain
Associated with del(5q)
<1% Unknown
DNMT3A 12–18% Unfavourable in patients without SF3B1 mutations 2–10% Uncertain
EZH2 5–10% Unfavourable 5–12% Unfavourable
IDH1 <5% Uncertain <1% Uncertain
IDH2 <5% Uncertain 5–10% Unfavourable
JAK2 <5% MDS with del(5q), 5–7% 2–10% Associated with MP-CMML
KRAS 5–10% Uncertain 10–20% Unfavourable
Associated with MP-CMML
NRAS 5–10% Unfavourable 10–20% Unfavourable
Associated with MP-CMML
RUNX1 10–15% Unfavourable
Can be of germline origin
10–30% Unfavourable
SETBP1 <5% Unfavourable 5–10% Unfavourable
SF3B1 20–30%
80% MDS-RS
Associated with RS
Favourable
5–10% Unknown
SRSF2 10–15% Unfavourable 30–50% Uncertain
STAG2 5–10% Unfavourable 5–10% Unfavourable
TET2 20–25% Uncertain 45–60% Uncertain
TP53 8–12% Unfavourable
Associated with CK (50%), del(5q) (15–20%)
Lower response rate to lenalidomide
Can be of germline
<5% Unfavourable
U2AF1 8–12% Unfavourable 5–10% Unfavourable
ZRSR2 5–10% Unfavourable 5–10% Uncertain
CK, complex karyotype; CMML, chronic myelomonocytic leukaemia; HMA, hypomethylating agents; MDS, myelodysplastic syndrome; MDS-RS,
MDS with ring sideroblasts; MP-CMML; myeloproliferative CMML; NK, normal karyotype; RS, ring sideroblasts.
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Other genes recurrently mutated in MDS and CMML
that are involved in other cellular processes, include TP53,
SETBP1, BCOR and BCORL1 (Bejar et al, 2011; J€adersten
et al, 2011; Damm et al, 2013a,2013b; Bejar et al, 2014;
Elena et al, 2016). TP53 mutations are more frequent in
high risk patients and are associated with adverse prognosis
features, including advanced disease, complex karyotypes,
monosomal karyotypes, excess of blasts, severe thrombocy-
topenia and therapy-related MDS (Kita-Sasai et al, 2001;
Bejar et al, 2011; Kulasekararaj et al, 2013; Ok et al, 2015).
TP53 mutations are associated with a very poor prognosis
in all MDS subtypes, including patients who have under-
gone an haematopoietic stem cell transplantation (Bejar
et al, 2011; Kulasekararaj et al, 2013; Bejar et al, 2014).
TP53 mutations are also associated with the presence of del
(5q) and with a lower response rate to lenalidomide treat-
ment in these patients (J€adersten et al, 2011; Meggendorfer
et al, 2017).
Myeloid neoplasms with germline predisposition
Although most cases of MDS or AML are sporadic diseases,
a number of cases arise as the result of genetic predisposition
due to the presence of inherited germline mutations, which
has led the WHO classification to include a new section on
myeloid neoplasms with germline predisposition. This sec-
tion comprises cases of MDS, MDS/MPN and AML that
arise on the background of a predisposing germline mutation
Table II. List of GESMD-recommended genes for studying the clinical management of MDS and CMML.
Gene Region Type of mutation
Frequency
MDS CMML
ASXL1 Exons 10–13 Nonsense, frameshift 5–25% 40–50%
Codons: all
CSNK1A1 Exons 2–4 Missense 5–10% <1%
Codons: all
DNMT3A Complete coding region All 12–18% 2–10%
Hotspot codon: R882
EZH2 Complete coding region Nonsense, frameshift 5–10% 5–12%
Codons: all
IDH1 Exon 4 Missense <5% <1%
Hotspot codon: R132
IDH2 Exon 4 Missense <5% 5–10%
Hotspot codons: R140 and R172
JAK2 Complete coding region Missense <5% 2–10%
Hotspot codon: V617F
KRAS Exons 2 and 3 Missense 5–10% 10–20%
Hotspot codons: G12, G13, Q61 and G146
NRAS Exons 2 and 3 Missense 5–10% 10–20%
Hotspot codons: G12, G13 and Q61
RUNX1 Complete coding region Nonsense, frameshift 10–15% 10–30%
Codons: all
SETBP1 Exon 4 Missense <5% 5–10%
Codons: 858–870
SF3B1 Exons 10–16 Missense 20–30%
80% RS
5–10%
Codons: 622–781
SRSF2 Complete coding region Missense 10–15% 30–50%
Hotspot codon: P95
STAG2 Complete coding region Nonsense, frameshift, splicing 5–10% 5–10%
Codons: all
TET2 Complete coding region All 20–25% 45–60%
Codons: 1134–1444 or 1842–1921
TP53 Complete coding region All 8–12% <5%
Codons: all
U2AF1 Exons 2–6 Missense 8–12% 5–10%
Hotspot codons: S34 and Q157
ZRSR2 Complete coding region Nonsense, frameshift 5–10% 5–10%
Codons: all
GESMD, Spanish Group of MDS; CMML, Chronic Myelomonocytic Leukaemia; MDS, Myelodysplastic Syndrome; RS, ring sideroblasts.
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Table III. Other myeloid-related genes more frequent in AML, MPN and other MDS/MPN.
Gene
Region
Frequent mutations Type of mutation
Frequency
MDS (%) CMML (%)
Frequent in myeloproliferative neoplasms
CALR Exon 9
Codons: all
Frameshift <1 <1
CBL Exons 8 and 9
Codons: 366–420
Missense <5 8–18
CSF3R Complete coding region
Hotspot codons: 618
Missense <1 3–4
GATA2 Exons 2 and 6
Codons: all
Missense, frameshift <5 <1
MPL Complete coding region
Codons 505 and 515
Missense <1 <1
NF1 Complete coding region
Codons: all
Nonsense, frameshift, splicing <5 <5
PTPN11 Exons 3 and 7
Codons: all
Missense <1 4
Frequent in acute myeloid leukaemia
BCOR Complete coding region
Codon: all
All <5 <5
BCORL1 Complete coding region
Codons: all
Nonsense, frameshift <1 <1
CEBPA Complete coding region
Codons: all
Missense, frameshift <5 <5
ETV6 Complete coding region
Codons: all
Nonsense, frameshift <5 <1
FLT3 Exons 13–15 and 20
Hotspot codons: FLT3-ITD and D835
Missense, frameshift <5 <5
KIT Exons 2, 8–11, 13 and 17
Codons: all
Missense, frameshift <3 <1
NPM1 Exon 11
Hotspot codons: W288
Frameshift <5 <5
WT1 Exons 7 and 9
Codons: all
Missense, frameshift <3 <3
CMML, chronic myelomonocytic leukaemia; ITD, internal tandem duplication; MDS, myelodysplastic syndrome.
TP53
CBL, JAK2, NRAS, KRAS, MPL, NF1, PTPN11, KIT, FLT3
RUNX1, GATA2, ETV6
SMC1A, SMC3, RAD21, STAG1, STAG2
DNMT3A, TET2, IDH1/2, ASXL1, EZH2
SF3B1, SRSF2, U2AF1, ZRSR2
0 20 40 60 80 100
DNA damage response
Signal transduction
Transcription factors
Cohesins
Epigenetic regulators
Splicing factors
Mutation frequency (%)
Fig 1. Classification of frequently mutated genes in MDS and CMML according to their functional category (modified from Kennedy & Ebert,
2017; Kennedy & Ebert, 2017).
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(Arber et al, 2016). Several genes have been associated with a
genetic predisposition to myeloid malignancies, including
ANKRD26, CBL, CEBPA, DDX41, ELANE, ETV6, GATA2,
GSKIP, MPL, NF1, SAMD9, SAMD9L, PTPN11, RUNX1,
SRP72 and TP53, among others (Kennedy & Shimamura,
2019). The majority of these genes are included in myeloid-
related targeted panels focused on somatic mutations. In
addition, recent studies suggest that the frequency of germ-
line variants in some of these genes, like DDX41, may be
underappreciated, suggesting that they should also be con-
sidered for inclusion in a panel of recommended genes
(Berger et al, 2017; Tawana et al, 2018). This may be nota-
bly relevant in the context of the search for a related donor.
Considering all the above, when performing targeted
sequencing in MDS patients, the possibility of detecting a
germline mutation must be considered. Although a variant
allele frequency (VAF) close to 50% or 100% may be sug-
gestive of a germline mutation, its nature should be con-
firmed using a control germline sample before acting on it,
and should always be evaluated in the clinical and familial
context of each patient. Even though germline genetic pre-
disposition is frequently associated with MDS with early
onset (children and young adults), it is increasingly recog-
nized also in MDS cases diagnosed in advanced ages. The
prevalence of hereditary myeloid malignancies has not been
clearly established but is suspected to concern at least 5%
of adult patients with MDS/AML (Tawana et al, 2018). In
addition, currently known MDS/AML predisposition genes
account for only 25% of familial cases, so other risk loci
remain to be discovered (Tawana et al, 2018). When a
germline mutation is confirmed, referral of patients to pro-
fessionals with expertise in cancer predisposing syndromes
and in genetic counselling is recommended, due to the need
for highly specialized and rapidly advancing evaluations and
tailored treatments for these patients (Godley & Shimamura,
2017).
Clonal haematopoiesis of uncertain significance
Recurrent somatic mutations in MDS-associated genes, such
as DNMT3A, TET2, ASLX1, TP53 and JAK2 genes, have been
identified in the peripheral blood of healthy individuals with
advanced age and normal blood counts (Genovese et al,
2014; Jaiswal et al, 2014; Xie et al, 2014). These mutations,
usually detected at very low VAFs (<10%), provide a selective
advantage to the haematopoietic stem cells in which they
occur, but cells still maintain the ability to differentiate into
circulating leucocytes (Steensma et al, 2015). This phe-
nomenon has been defined as clonal haematopoiesis of inde-
terminate potential (CHIP) (Table IV) (Steensma et al,
2015). The incidence of CHIP increases with age, with more
than 10% of healthy people older than 70 years of age carry-
ing a mutation in one of those genes (Genovese et al, 2014;
Jaiswal et al, 2014). These individuals have an increased risk
of cardiovascular disease and a higher risk of developing an
haematological malignancy, although thankfully the rate of
malignant transformation is very low (05–1% per year)
(Jaiswal et al, 2014, 2017). This risk increases when the VAFs
are higher (>10%) or more than one mutation is detected.
In addition, recent studies have shown that patients with
solid tumours who have CHIP before being exposed to treat-
ment, are at increased risk of developing a therapy-related
myeloid neoplasm (TRMN) (Takahashi et al, 2013; Gillis
et al, 2017). Factors that influence the natural history of
CHIP are currently under investigation, but it is known that
the acquisition of further mutations drives the progression of
CHIP to overt malignancy.
Apart from healthy individuals, mutations in these MDS-
associated genes can also be detected in 35% of patients with
persistent blood cytopenias for which no explanation is
apparent, usually called idiopathic cytopenias of undeter-
mined significance (ICUS) (Table IV). These cases, that pre-
sent with both clonal haematopoiesis and cytopenias, are
designated clonal cytopenias of uncertain significance
(CCUS). Patients with CCUS are at a higher risk of develop-
ing a myeloid malignancy compared to those individuals
with CHIP not presenting any cytopenia, especially in the
presence of two or more mutations or if a single mutation in
a splicing gene is detected (Arber et al, 2016; Bejar, 2017;
Jaiswal et al, 2017) (Table IV). In addition, average VAFs in
patients with CCUS (30–40%) are higher compared to those
found in CHIP.
Taking all these observations into account, when perform-
ing NGS routine tests in a patient with an indication of
MDS, diagnosis should always be performed in the context
of other laboratory and clinical data.
Table IV. Characteristics of CHIP, ICUS, CCUS and MDS.
CHIP ICUS CCUS MDS
Cytopenia No Yes (≥1) Yes (≥1) Yes (≥1)
Dysplasia No No, or minimum No, or minimum Yes
Mutations Yes (n = 1) No Yes (n ~ 1, 6) Yes >85% (n ~ 2, 6)
VAF 2–12% – 30–40% 30–50%
Progression Risk 0.5–1% per year >10% in 5 years >85% in 5 years
CCUS, clonal cytopenia of uncertain significance; CHIP, clonal haematopoiesis of uncertain significance; ICUS, idiopathic cytopenia of uncertain
significance; MDS, myelodysplastic syndrome; VAF, variant allele frequency.
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Sequencing workflow and quality criteria
Targeted NGS panels commonly include a selected number
of specific genes, or coding regions within genes that are
clinically-actionable in the disease of interest, or that are
known to harbour mutations that contribute to the patho-
genesis of the disease. Focusing on a limited set of genes
allows greater depth of coverage for increased analytical sen-
sitivity and specificity. Thus, targeted sequencing is often
used in clinical care because, while keeping the cost relatively
low, it provides greater confidence and facilitates the inter-
pretation of the findings in their clinical context. The choice
of sequencing strategy will depend on several factors, includ-
ing size of the panel, sequencing platform, turnaround time
(TAT) for reporting the results and cost per sample.
Panel design strategy
When designing a custom panel, it is recommended to select
targets and transcripts only from genes with potential clinical
relevance. There are several available online tools that can be
used to design the specific primers/probes to enrich the tar-
gets of interest. Although custom panels are usually flexible
and can be modified over time, they require a long process
of optimization and validation, which is skipped when using
off-the-shelf panels. On the other hand, commercial panels
offer a closed design, but do not require a previous design
phase and are already optimized. Of note, these panels are
commercially available as ready-to-use, but quite often they
still require validation in each laboratory.
Library preparation
In MDS and CMML, as in most haematological neoplasms,
it is recommended to perform molecular analyses on bone
marrow-derived cells. Some studies suggest that, due to the
high sensitivity of NGS, there is little difference between
bone marrow and peripheral blood samples (Duncavage
et al, 2017; Martin et al, 2018). Therefore, if bone marrow
is not available, peripheral blood can be useful, especially
for molecular monitoring or in myeloproliferative disorders
like CMML. Although DNA from fresh samples is the opti-
mal input material, targeted NGS can be performed on any
DNA sample as long as the quality and quantity are suffi-
cient. DNA purity can be measured by spectrophotometry
(i.e. Nanodrop device, Thermo Fisher Scientific, Waltham,
MA, USA), while DNA integrity can be assessed by capil-
lary electrophoresis (i.e. Tape Station or Bioanalyzer
devices, Agilent, Santa Clara, CA, USA). Input DNA and
DNA libraries should be quantified using a fluorometric
assay (i.e. Qubit or Quant-iT PicoGreen, Thermo Fisher
Scientific) that can distinguish and measure the concentra-
tion of double-stranded DNA. The manufacturer’s recom-
mendations should be strictly followed during library
preparation.
Two main strategies for library preparation are widely
used in targeted NGS: amplicon-based and hybrid-capture-
based. Amplicon panels are based on the use of specific pri-
mers and the amplification of the regions of interest by poly-
merase chain reaction (PCR)-based methods (single or
multiplex PCR, or emulsion PCR). On the other hand, target
enrichment is performed in capture panels using probe
hybridization-based methods. In both cases, DNA fragments
generated during library preparation contain adapter
sequences on both ends, which are complementary to plat-
form-specific sequencing primers. Samples can be tagged
with a unique oligonucleotide barcode that enables pooling
of different patient samples in the same sequencing run
(Table S1). In addition, some strategies use unique molecular
barcodes that tag each original DNA fragment and allow
identification and removal of PCR duplicates during bioin-
formatic processing of sequencing data.
Sequencing platforms
Sequencers for NGS, based on the ability to perform an ele-
vated number of chemical reactions in parallel, are increas-
ingly being used in the clinical setting. Sequencing
instruments can be classified according to the mean read
length (short or long), the type of sequencing (single-end
and paired-end sequencing) and the sequencing chemistry
(mainly by synthesis, ligation or hybridization). Multiple fac-
tors should be considered when choosing a sequencing plat-
form, such as run time, size of sequenced region, required
depth of coverage, read length, TAT requirements and cost
per sample. According to the GESMD, Illumina (San Diego,
CA, USA) and Thermo-Fisher Scientific, short-read sequenc-
ing platforms are ideal for the implementation of targeted
deep sequencing in diagnostic laboratories (Table S2).
There is a number of sequencing parameters that define
the scope and quality of data output of a given NGS technol-
ogy: sequencing capacity, type and length of the reads,
sequencing output, depth of coverage, percentage of reads
mapped correctly and uniformity of the reads (Table S3).
Some of these parameters can be influenced by other vari-
ables, such as input DNA quality, adequate library prepara-
tion, correct design of the primers/probes, choice of
sequencing platform, and the initial estimation of the num-
ber of required reads. Regarding the depth of coverage, we
recommend that ≥95% of the bases targeted in the panel
design are covered by at least 100 reads (≥1009), and that
the mean coverage for each sample is ≥10009. This will
enable the identification of variants with a sensitivity of at
least 5% in most regions, as long as variant quality criteria
are fulfilled (we recommend the presence of at least 25 reads
for the alternative allele). Of note, even though this is our
recommendation, less conservative approaches are also likely
to be highly valid, especially for certain hotspot locations,
and should be validated in each laboratory. The minimum
output required per library can be estimated by taking into
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account the intended depth of coverage together with the
size of the panel (including on- and off-target regions). It is
recommended that the percentage of on-target mapped reads
is higher than 70%.
Test validation
During test development, iterative cycles of performance
optimization should be executed until all the different com-
ponents of the assay are optimized, including panel design,
library preparation conditions, sequencing parameters, num-
ber of samples that should be pooled in order to achieve the
desired coverage level, as well as analysis settings and pipe-
line. TAT for data reports need to be estimated and should
be clinically appropriate. Once the entire panel conditions
have been established, the assay needs to be validated, and
performance characteristics (such as sensitivity, specificity
and reproducibility) should be determined.
Two rounds of validation should be consecutively per-
formed. Firstly, a technical validation round aimed at evalu-
ating the quality of the design and identifying the regions
with poor coverage. For technical validation, input DNA
requirements, library generation and sequencing should be
performed, strictly following manufacturer’s recommenda-
tions. During this process, the percentage of bases covered at
different depths of coverage should be determined, as well as
the regions with low or no coverage, which should be then
redesigned or removed from the design. Biological replicates
should also be assessed, including sequencing two libraries
generated from the same input DNA and sequencing two
libraries from two different DNA extractions of the same
sample. Recurrent artefacts should also be identified. For
example, variants that appear at greater frequency than
expected in a large cohort or that have reads supporting
them in a large number of samples, especially if they all clus-
ter at similar VAFs, are likely to be technical artefacts. Gener-
ation of internal databases with known technical artefacts
can be helpful in order to filter these artefacts out during the
analysis-filtering steps. Secondly, a clinical validation round
should also be performed with the aim of determining if the
designed test is able to detect known alterations associated
with the disease of interest. In order to do so, previously
characterized samples with known SNVs and/or indels,
should be analysed with the new test. Whenever possible,
previously undescribed variants and complex indels should
be validated by other technologies, such as Sanger sequenc-
ing, amplification refractory mutation system (ARMS)-PCR,
allele-specific oligonucleotide (ASO)-PCR, digital PCR or
other NGS platforms. Finally, sequencing of serial dilutions
from the same sample will help to determine the sensitivity
of the test.
In NGS, standards for TAT should be established by each
laboratory based on the clinically proper indication for test-
ing. Multiplexing samples from different diseases and using
small-scale sequencing systems can help reduce TAT. In real
world scenario of diagnosis of MDS and CMML, these TAT
should be consistent with other cytogenetic tests (karyotype
and fluorescence in situ hybridisation), and should not
exceed, for most cases, 15 working days (Rack et al, 2019).
Urgent referrals should be prioritized and, for these cases,
results should try to be reported within 10 days.
Data analysis and variant filtering
Data analysis
The goal of data analysis is to use bioinformatic tools within
an analysis pipeline in order to transform the raw data com-
ing from the sequencer into a list of variants that can be
visualized, filtered and interpreted. The challenge of data
analysis includes the huge number of available tools, the con-
stantly evolving analysis pipelines and the lack of consensus
regarding which tools to use. Typical NGS data analysis
workflows include base calling, read alignment variant calling
and variant annotation. Data analysis steps and tools that are
recommended, and most commonly used, by the GESMD
are summarized in (Data S1, Tables S4, S5). It should be
noted that several open-source and commercial tools have
been developed to facilitate NGS data analysis in the clinical
setting, in the form of user-friendly interfaces. Some of these
tools, used by the GESMD, include MiSeq Reporter (Illu-
mina), Variant Studio (Illumina), IonReporter (Thermo-
Fisher Scientific), DNAnexus (DNAnexus, Santa Clara, CA,
USA) and Sophia DDM (Sophia Genetics, Lausanne, Vaud,
Switzerland).
Variant filtering
After data analysis, variant filtering should then be per-
formed in order to obtain a list of candidate variants that
will later be categorized, interpreted and reported. Of note,
variant filtering criteria should always be updated according
to the advances made in NGS technologies and in the disease
of interest. The variant filtering workflow proposed by the
GESMD is described in Table V and Fig 2.
Variant interpretation and categorization
Interpretation systems for classifying variants are useful to
standardize the way in which variants are reported to clini-
cians. In response to the classification discrepancies that
often exist between laboratories, the use of unified guidelines
is highly recommended. On one hand, germline variants clas-
sification systems aim to classify variants according to their
pathogenicity in a given disease (Richards et al, 2015; Mat-
thijs et al, 2016). A joint consensus between the American
College of Medical Genetics and Genomics and the Associa-
tion for Molecular Pathology, for example, proposes updated
standards for variant assessment and promotes the systematic
evidence-based classification of variants found in Mendelian
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disorders (Richards et al, 2015). On the other hand, in can-
cer, somatic variants are assessed for diagnostic, prognostic,
predictive and/or therapeutic impact in the context of
tumour site and histology (Sukhai et al, 2016). Given their
relevance, a system to prioritize variants detected by whole
exome sequencing (WES) as well as two somatic tier-based
variant classification systems have been reported in the litera-
ture (Van Allen et al, 2014; Sukhai et al, 2016; Li et al,
2017). Sukhai et al (2016) propose a classification scheme in
which variants are categorized from Class 1 (highest priority)
to Class 5 depending on the influence that the variant shows
on diagnosis, prognosis or treatment of the specific tumour
being evaluated. Similarly, Li et al (2017) classify variants
from Tier I (Variants with Strong Clinical Significance) to
Tier IV (Benign or Likely Benign Variants) based on the clin-
ical impact of a given variant, which is determined according
to currently available evidence. It is of high importance to
include a separate category for benign variants, to inform
clinicians and patients and to reduce the burden on laborato-
ries (Hoskinson et al, 2017). Based on our experience, the
Table V. Variant filtering workflow detailed information proposed by the GESMD.
Step Description
Variant pre-filtering
Filter according to variant region • Preserve variants located in:
◦ Coding regions (exonic)
◦ Splicing sites (12 bp)
• Remove variants located at: intergenic regions, downstream, upstream, non-coding RNAs, intronic
regions far from splicing sites.
Remove sequencing errors • Remove sequencing errors non-detected previously by the software of analysis. Some commonly
detected errors include:
◦ Non-uniform coverage in the region flanking the variant
◦ Strand bias: variants only covered by forward or reverse reads
◦ Small indels located at repetitive and homopolymeric regions
◦ Edge effect: variants located at the end of the amplicon
• A genomic viewer that can open alignment files (BAM or SAM), such as IGV (Broad Institute), should
be used to visualize the data and identify the errors (Robinson et al., 2011).
Variant filtering
Polymorphisms • MAF refers to the frequency at which a variant occurs in a given population. Variants with a
MAF ≥ 1% are considered as polymorphisms in somatic mutation analysis. The clinical implication of
polymorphisms in MDS and CMML is currently not known; therefore, we recommend not reporting
these variants for now.
• Population databases provide comprehensive information about frequencies of alternative (minor) alle-
les at a given locus in a large cohort of individuals. The following population databases can be used to
identify and filter out polymorphisms: 1000 Genomes Project, Exome Variant Server, ExAC, dbSNP,
dbVar and gnomAD.
Synonymous variants • Synonymous (or silent) variants are SNVs that do not alter the encoded amino acid sequence. Their
clinical relevance in MDS and CMML is unknown. Based on this current knowledge, we recommend
that these variants should be filtered out for now, except well annotated pathogenic variants (i.e. TP53
synonymous variants that are known to affect splicing).
Variants in UTR regions • The clinical relevance of variants located at 3’UTR or 5’UTR regions is currently unknown. Based on
this we recommend that these variants should be filtered out for now.
Quality criteria
Coverage • Coverage of the locus: ≥1009. We recommend that the genomic position in which the variant is
located is covered by at least 100 reads.
• Coverage of the variant: ≥259. We recommend the presence of at least 25 reads for the alternative
allele.
• If the variant does not fulfil the quality criteria, sequencing should be repeated or the variant should
be validated by a different technique.
BAM, binary alignment map; bp, base pairs; CMML, chronic myelomonocytic leukaemia; GESMD, Spanish MDS Group; IGV, Integrative Geno-
mics Viewer; MAF, minor allele frequency; MDS, myelodysplastic syndrome; SAM, sequence alignment map; SNV, single nucleotide variant;
UTR, untranslated region.
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use of specific standard terminology (pathogenic, likely
pathogenic, uncertain significance, likely benign and benign)
facilitates the use of classification systems, especially for clini-
cians.
In light of this, and based on the same tier-based classifi-
cation system of the American Association for Molecular
Pathology, American Society of Clinical Oncology and Col-
lege of American Pathologists (Li et al, 2017), we propose a
system to classify somatic variants detected in myeloid neo-
plasms (Fig 2).
Tools for variant interpretation
In order to properly classify and annotate the detected
somatic variants, several currently available repositories and
genomic databases can be used. Before using these data-
bases, clinical laboratories should make an effort to under-
stand their content and note their limitations (Li et al,
2017). Likewise, establishing and consulting an in-house
database of variants identified in the laboratory is recom-
mended. The tools recommended by the GESMD are listed
in Table VI.
Reference sequence databases. Reference sequence databases
encompass the human reference genome and related infor-
mation for the unequivocal localization of a variant in the
genome. These databases annotate variant location (coding,
non-coding, splicing site or untranslated region) and the
strand representation (positive or negative) within the corre-
sponding gene. Frequently consulted resources include
Ensembl [European Molecular Biology Laboratory- European
Bioinformatics Institute (EMBL-EBI) and the Wellcome
Trust Sanger Institute; http://www.ensembl.org/index.htm],
RefSeq [National Center for Biotechnology Information
(NCBI) Reference Sequence Database; https://www.ncbi.nlm.
nih.gov/refseq] and Locus Reference Genomic (LRG, NCBI
and EMBL-EBI; https://www.lrg-sequence.org/). This infor-
mation is essential for the correct nomenclature of the
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Fig 2. Proposed workflow for variant filtering and categorization. UTR, untranslated region. [Colour figure can be viewed at wileyonlinelibrary.com]
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Table VI. List of web resources useful for variant interpretation.
Database Website URL
Reference sequence
NCBI reference sequence database https://www.ncbi.nlm.nih.gov/genome
Ensembl genome browser http://www.ensembl.org/index.htm
Locus reference genomic https://www.lrg-sequence.org/
RefSeqGene https://www.ncbi.nlm.nih.gov/refseq
MitoMap https://www.mitomap.org/MITOMAP/HumanMitoSeq
UCSC genome browser https://genome.ucsc.edu/cgi-bin/hgTables
Population databases
dbSNP https://www.ncbi.nlm.nih.gov/snp/
Exome variant server http://evs.gs.washington.edu/EVS/
1000 genomes project http://browser.1000genomes.org
dbVar https://www.ncbi.nlm.nih.gov/dbvar
Exome Aggregation Consortium (ExAC) http://exac.broadinstitute.org/
Genome Aggregation Database (gnomAD) http://gnomad.broadinstitute.org/
Short genetic variation https://www.ncbi.nlm.nih.gov/snp
Somatic and constitutional variants databases
National Cancer Institute’s Genome Data Commons https://gdc.cancer.gov
Catalogue of Somatic Mutations in Cancer (COSMIC) http://cancer.sanger.ac.uk/cosmic
IARC TP53 mutation database http://p53.iarc.fr/TP53GeneVariations.aspx
TP53 website http://p53.fr/
Personalized cancer therapy https://pct.mdanderson.org
cBioPortal http://www.cbioportal.org
Intogen https://www.intogen.org/search
ClinicalTrials.gov https://clinicaltrials.gov
Pediatric Cancer Genome Project http://explorepcgp.org
My Cancer Genome http://www.mycancergenome.org
International Cancer Genome Consortium (ICGC) https://dcc.icgc.org
The Cancer Genome Atlas (TCGA) https://cancergenome.nih.gov/
VarSome The Human Genomic Variant Search Engine https://varsome.com
DECIPHER https://decipher.sanger.ac.uk/
ClinVar http://www.ncbi.nlm.nih.gov/clinvar
Online Mendelian Inheritance in Man (OMIM) https://www.omim.org/
Human Gene Mutation Database (HGMD) http://www.hgmd.cf.ac.uk/ac/index.php
Leiden Open Variation Database (LOVD) http://www.lovd.nl
In-house laboratory databases
RESMDmol https://www.gesmd.es/carrerasresearch/index.php
Algorithms for in silico prediction
PolyPhen2 http://genetics.bwh.harvard.edu/pph2
SIFT http://sift.jcvi.org
Mutation Assessor http://mutationassessor.org
Mutation Taster http://www.mutationtaster.org
PROVEAN http://provean.jcvi.org/index.php
CoVEC https://sourceforge.net/projects/covec/files
CADD http://cadd.gs.washington.edu
GERP++ http://mendel.stanford.edu/sidowlab/downloads/gerp/index.html
PhyloP and PhastCons http://compgen.bscb.cornell.edu/phast
ConSurf http://consurftest.tau.ac.il
FATHMM http://fathmm.biocompute.org.uk
PANTHER http://www.pantherdb.org/tools/csnpScoreForm.jsp
PhD-SNP http://snps.biofold.org/phd-snp/phd-snp.html
SNPs & GO http://snps-and-go.biocomp.unibo.it/snps-and-go
Align GVGD http://agvgd.iarc.fr/agvgd_input.php
MAPP http://mendel.stanford.edu/SidowLab/downloads/MAPP/index.html
MutPred http://mutpred.mutdb.org
nsSNPAnalyzer http://snpanalyzer.uthsc.edu
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variants according to the Human Genome Variation Society
(HGVS) (Li et al, 2017).
Population databases. Population databases are useful for
obtaining the frequency of variants at a given locus in a vari-
ety of geographically distinct populations (Cottrell et al,
2014; Richards et al, 2015). They are commonly used to filter
out polymorphic variants based on an established cut-off of
minor allele frequency (MAF). Although a standardized MAF
to discriminate between polymorphic or benign variants has
not been established yet, current practice within GESMD sets
1% as the cut-off point in studies of somatic variants. Addi-
tionally, an ethnic specificity of the variant should be consid-
ered based on the ethnic background of the patient. Finally,
we would emphasise a cautionary note when consulting these
databases, as they were built under the assumption that the
population included in them is healthy, but some somatic
variants may accidentally have been included as well. For
example, common hotspot mutations, such as DNMT3A
R882 or JAK2 V617F, can be found in some of these data-
bases and therefore a whitelist of known hotspot mutations
could be useful to rescue these variants.
Recommended population databases include The Database
of Short Genetic Variation (dbSNP, the NCBI database of
genetic variation; https://www.ncbi.nlm.nih.gov/snp/), Exome
Variant Server (EVS, NHLBI GO Exome Sequencing Project;
http://evs.gs.washington.edu/EVS/), 1000 Genomes Project
(International Genome Sample Resource, IGSR; http://browse
r.1000genomes.org), Exome Aggregation Consortium (ExAC,
Broad Institute; http://exac.broadinstitute.org/) and Genome
Aggregation Database (gnomAD, Broad Institute; http://gno
mad.broadinstitute.org/). Databases such as ExAC or gno-
mAD are more accurate than dbSNP when it comes to
filtering polymorphisms and neutral variants.
Somatic and germline variants in clinical databases. Both
somatic and germline variants are included in clinical data-
bases. The incidence and prevalence of a variant is often
detailed in different subtypes of cancers and functional pre-
diction algorithms are provided to categorize the variants
according to their pathogenicity. Frequently, clinical data-
bases also include information for accurate annotation and
prioritization of somatic variants; bibliographic references
with or without systematic review; additional information
about the tissue in which the variant has been described;
outcome disease data or targeted therapies, among others.
An example is the National Cancer Institute’s Genome Data
Commons (https://gdc.cancer.gov), which contains all the
genomic data generated at the National Cancer Institute, and
which includes the well-known databases of The Cancer Gen-
ome Atlas (TCGA; https://cancergenome.nih.gov/), the Ther-
apeutically Applicable Research to Generate Effective
Therapies (TARGET; https://ocg.cancer.gov/programs/target),
and the Cancer Genome Characterization Initiative (CGCI;
https://ocg.cancer.gov/programs/cgci). Another public data-
base is the Catalog of Somatic Mutations in Cancer (COS-
MIC; http://cancer.sanger.ac.uk/cosmic) from the Wellcome
Sanger Institute, which contains millions of somatic varia-
tions described in numerous types of tumours and has also
recently included intron variants. However, the information
provided in these databases is not always up-to-date. In addi-
tion, a poor representation of pathological diagnostic stan-
dards is detected as well as a lack of an exhaustive validation
of the findings and/or the sources from which the included
variants were extracted.
Germline variants are also usually detected upon tumour
sequencing. Such variants may be associated with cancer pre-
disposition syndromes. To evaluate them, there are several
germline mutations databases, such as Human Gene Muta-
tion Database (Institute of Medical Genetics; http://www.
hgmd.cf.ac.uk/ac/index.php) or ClinVar (NCBI; http://www.
ncbi.nlm.nih.gov/clinvar).
Finally, for TP53 gene variant interpretation, the Interna-
tional Agency for Research on Cancer (IARC) TP53 Database
(WHO; http://p53.iarc.fr/TP53GeneVariations.aspx) and
TP53 Website (Centre de Recherche des Cordeliers and
Karolinska Institute; http://p53.fr/) are useful resources for
evaluating their impact in haematological malignancies,
because they include the frequencies of the variants observed
in both the somatic and germinal contexts.
Table VI. (Continued)
Database Website URL
Condel http://bg.upf.edu/condel/home
LRT http://www.genetics.wustl.edu/jflab/lrt_query.html
DANN https://omictools.com/dann-tool
Splice site prediction
Human splicing finder http://www.umd.be/HSF3
MaxEntScan http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html
NetGene2 http://www.cbs.dtu.dk/services/NetGene2
NN plice http://www.fruitfly.org/seq_tools/splice.html
GeneSplicer http://www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml
NNSplice http://www.fruitfly.org/seq_tools/splice.html
FSPLICE http://www.softberry.com/berry.phtml?topic=fsplice&group=programs&subgroup=gfind
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In-house laboratory databases. We recommend that each
clinical laboratory should establish an in-house database to
provide consistent variant annotation and categorization, to
determine the frequency of mutations and to identify plat-
form-specific artefacts or potential false-positive variants. A
continuous review of new publications, clinical trials and
databases used in variant interpretation, which are regularly
updated, should be carried out to ensure that variant annota-
tion is up-to-date. To increase the quality of interpretation,
we recommend that in-house databases are complemented
with further relevant annotation, including results from other
techniques such as morphology, cytogenetic and
immunophenotyping, because NGS results should always be
combined and interpreted in the context of other laboratory
and clinical diagnostic data. Moreover, it would be extremely
useful to share those internal databases with other centres/
laboratories that perform similar determinations. Indeed, the
GESMD is making that effort by building the RESMDmol
database (https://www.gesmd.es/carrerasresearch/index.php),
in view of facilitating the homogenization of results informed
in the clinical reports.
Functional consequence of the variant. In silico predictive
algorithms estimate the possible deleterious consequences of a
variant on the encoded protein of a given gene. The criteria
used to determine this effect varies across different tools.
Algorithms designed to predict the functional consequence of
a missense variant are commonly based on the evolutionary
conservation of an amino acid or nucleotide, the location and
context within the protein sequence and the biochemical con-
sequence of the amino acid substitution (Brunak et al, 1991;
Vreeswijk et al, 2009; Thusberg et al, 2011). In silico tools have
also been developed to evaluate the consequence of splicing
variants related to the creation or loss of splice sites at the
exonic or intronic regions (Thusberg et al, 2011; Houdayer
et al, 2012). However, in the context of cancer, the interpreta-
tion of these predictions is usually not easy, especially for
gain-of-function mutations. Therefore, it is recommended
that least four different prediction algorithms should be used
to analyse each variant, although the obtained output should
never be used as sole evidence for clinical decision making, as,
to date, there is no consensus about the relevance of each pre-
dictor, nor about how to combine outputs from different pre-
diction algorithms (Li et al, 2017).
In the case of variants with available information about
their functional effect, two scenarios can be considered. On
one hand, when the pathogenicity of the affected gene is
associated with a loss of function, frameshift variants must
be interpreted as probably pathogenic, as long as the variant
does not affect the last exon of the gene, unless the
pathogenicity of those variants affecting the last exon has
been validated (i.e. variants in ASXL1 and CALR). Loss of
function variants located at the last exon of a gene will need
evaluation according to other parameters, such as the type of
protein domain that is altered and the effect of other
proximity variants. Accordingly, these will be classified as
variants of uncertain significance or probably pathogenic. On
the other hand, when the pathogenicity of the affected gene
is associated with a gain-of-function, and a frameshift variant
is detected, this will be interpreted as a variant of uncertain
significance unless there is strong evidence of pathogenicity
based on functional studies in the literature.
Criteria for variant classification
We recommend to interpret and report variants that fulfil all
three following criteria: (i) MAF < 1%, (ii) VAF ≥ 5% and
(iii) minor allele coverage ≥25 reads. Although we recom-
mend that cut-off of VAF ≥ 5% should be used, the analyst
should consider informing variants with lower allele frequen-
cies in particular cases, such as hotspot regions in genes with
clear clinical relevance, such as TP53 or JAK2. However, in
order to report variants with a VAF below 5%, the depth of
coverage must be increased to maintain, at least, the minor
allele coverage over 25 reads.
The GESMD proposes that variants should be categorised
according to the following criteria: (i) relevance of the
altered gene based on its actionability, defined as being rele-
vant for the diagnosis/classification, prognosis and/or treat-
ment (therapeutic target or related to sensitivity, toxicity or
resistance to therapy) of the disease; (ii) presence of the vari-
ant in clinical databases and published literature that indi-
cates the recurrence or pathogenicity of the identified
variant; (iii) tissue and/or tumour histology in which the
variant has been described; and (iv) in silico predictive algo-
rithms and functional studies.
Therefore, the categorization of the variant must be based
on its clinical impact on the specific disease and tissue under
study. Due to the importance of the definition of the action-
ability of a gene, we strongly recommend following the evi-
dence defined by Sukhai et al (2016). Of note, determining
the actionability of a gene will be particularly relevant when
using pan-haematological or oncological targeted NGS panels
that include genes which have not been previously described
in the disease of interest, as well as for WES and whole gen-
ome sequencing.
Variant classification system
According to our categorization criteria, variants will be clas-
sified into one of the following classes (Fig 2, Table VII):
Pathogenic (Tier I). Described in the literature as relevant
for the clinical management of MDS/CMML or other mye-
loid neoplasms. The variant affects an actionable gene and
has been established as a pathogenic variant in myeloid neo-
plasms.
Likely pathogenic (Tier II). Described in the literature but
with no established relevance in the clinical management of
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MDS or other myeloid neoplasms. The variant affects an
actionable gene but has been established as a pathogenic
variant in solid tumours or in non-myeloid haematological
neoplasms. This category also includes variants previously
not described for which predictive algorithms strongly clas-
sify them as pathogenic.
Variant of uncertain significance (VUS) (Tier II). Previously
described but with no sufficient evidence of its pathogenicity
on actionable MDS genes, other haematological neoplasms
or solid tumours. This category also includes variants not
previously described for which predictive algorithms cannot
strongly classify them into pathogenic or benign.
Likely benign (Tier IV) or benign (Tier V). Described in the
literature as clinically insignificant because it has no effect on
the protein. Frequently, these variants present MAF > 1%
and, sometimes, VAF of approximately 50% or 100%. These
levels of VAF may be indicative of the germline nature of the
variant and, therefore, are neither acquired nor tumour-spe-
cific. However, the VAF criterion should be considered with
caution, as there are somatic variants present in major clones
with high VAF. This category also includes variants previ-
ously not described for which predictive algorithms strongly
classify them as benign. We recommend that, to avoid confu-
sion, benign and likely benign variants should not be
included in the clinical report.
Clinical report
Next generation sequencing clinical reports should follow the
general professional organizations’ recommendations and
guidelines (Richardson, 2002; Rack et al, 2019), such as
avoiding long reports for the benefit of clarity, inclusion of
pagination, and reviewing and signing by, preferably, two
geneticists with the relevant expertise on haematological
malignancies. We recommend that the report includes (at
least) the information detailed below.
Patient identification
As in current standard tests, proper patient identification
should be incorporated in the clinical report, including two
unique patient identifiers, demographic data and referral
information (reason for referral, suspected or confirmed
diagnosis and clinical time point). Sample details should also
be provided (type, source and received date) as well as hospi-
tal and referring physician. A statement of signed informed
consent should also be made.
Methodology
Details on the methodology used should be specified, includ-
ing library preparation chemistry and sequencing instrument.
Regions included in the panel (genes according to theT
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Human Genome Organisation nomenclature, exons and hot-
spots) and low covered regions should be detailed. Analysis
settings, filters and cut-off values (such as minimum cover-
age or VAF) should be specified. The version of the human
reference sequence to which sequence reads are aligned
should also be included, as well as the clinical databases used
for annotation. Key quality control metrics and limitations
need also be listed.
Results and interpretation
A list of identified variants should be included in the results
section, annotated in accordance to the HGVS mutation
nomenclature. For each variant, we recommend including
the following information: gene, exon, nucleotide change,
protein change, type of variant (missense, frameshift, non-
sense, splicing), transcript RefSeq ID, variant ID from clinical
databases, VAF and position depth of coverage. When using
a variant classification system, the categorization of each
variant should be included and the used classification system
should be described. Regarding variant interpretation, we
recommend including a critical summary of the clinical rele-
vance of the variant in the disease of interest, including treat-
ment or referenced clinical trials information, if applicable.
For the categorization of the disease, the WHO 2017 nomen-
clature should be used (Arber et al, 2016). Further studies to
validate the significance of the results obtained should be
conducted when appropriate.
Conclusion
We have long awaited the introduction of NGS into the rou-
tine diagnostic armamentarium of myeloid malignancies.
Currently, an increasing number of laboratories are imple-
menting NGS procedures into the diagnostic algorithms of
patients with haematological malignancies, opening new
horizons for individualized clinical management of these
patients. It is therefore of major importance to standardize
the generation, analysis and clinical interpretation of NGS
data. To that end, the GESMD has expanded the present set
of guidelines, aiming at stablishing common quality
standards for the adequate clinical interpretation of NGS
results, hoping that this effort will ultimately contribute to
the benefit of patients with myeloid malignancies.
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